A real-world study assessing the real-world persistence rates and costs among patients with chronic migraine (CM) treated with onabotulinumtoxinA (onabotA [BOTOX]) or calcitonin gene–related peptide monoclonal antibody (CGRP mAb)
Latest Information Update: 31 May 2022
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Calcitonin-gene-related-peptide-monoclonal-antibody-4901
- Indications Migraine
- Focus Therapeutic Use
Most Recent Events
- 31 May 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022